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Background: Elderly patients are more vulnerable to toxicity from chemotherapy. Activating epidermal growth
factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to
EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for whom treatment was customized
based on EGFR mutation status.
Methods: We screened 57 chemotherapy-naïve patients with histologically or cytologically confirmed NSCLC, stage
IIIB or IV, aged 70 years or older, and with an Eastern Cooperative Oncology Group performance status 0 or 1, for
EGFR exon 19 codon 746–750 deletion and exon 21 L858R mutation. Twenty-two patients with EGFR mutations
received gefitinib; 32 patients without mutations received vinorelbine or gemcitabine. The primary endpoint was
the response rate.
Results: The response rate was 45.5% (95% confidence interval [CI]: 24.4%, 67.8%) in patients with EGFR mutations
and 18.8% (95% CI: 7.2%, 36.4%) in patients without EGFR mutations. The median overall survival was 27.9 months
(95%CI: 24.4 months, undeterminable months) in patients with EGFR mutations and 14.9 months (95%CI:
11.0 months, 22.4 months) in patients without EGFR mutations. In the gefitinib group, grade 3/4 hepatic
dysfunction and dermatitis occurred in 23% and 5% of patients, respectively. In patients treated with vinorelbine or
gemcitabine, the most common grade 3 or 4 adverse events were neutropenia (47%; four had febrile neutropenia),
anemia (13%), and anorexia (9%). No treatment-related deaths occurred.
Conclusions: Treatment customization based on EGFR mutation status deserves consideration, particularly for
elderly patients who often cannot receive second-line chemotherapy due to poor organ function or comorbidities.
Trial registration: This trial is registered at University hospital Medical Information Network-clinical trial registration
(www.umin.ac.jp/ctr/index/htm) with the registration identification number C000000436.* Correspondence: jp.shirofujita@gmail.com
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In many developed countries, lung cancer is the leading
cause of cancer death for both men and women. Ap-
proximately 80% to 85% of lung cancer subtypes are non-
small-cell lung cancer (NSCLC). Like other solid tumors,
NSCLC primarily occurs in the elderly and most patients
are diagnosed with advanced disease that is unsuitable
for surgery [1,2]. As the geriatric population inexorably
increases, more elderly patients with NSCLC will receive
anticancer agents for palliative intent. Because definite
potential exists for higher toxicity, attributed to progres-
sive organ failure and comorbidities, single-agent chemo-
therapy (using a third-generation agent) along with
platinum-based combinations is recommended for the
treatment of this population [3,4].
Theoretically, drug-induced adverse events (AEs) are
avoidable while maintaining anti-tumor effects by tar-
geting the critical molecule that drives proliferation of
and is solely present in cancer cells. After the success of
imatinib for treatment of BCR-ABL-dependent chronic
myelogenous leukemia [5,6], understanding the molecu-
lar basis of human cancer has been exploited to provide
targeted drugs. The epidermal growth factor receptor
(EGFR) is a receptor tyrosine kinase (TK) of the ErbB
family that has been implicated in cell proliferation and
survival [7]. EGFR is a target of the tyrosine kinase in-
hibitor (TKI) gefitinib (Iressa; AstraZeneca, Maccles-
field, United Kingdom), which has been approved for
NSCLC treatment in many countries. The EGFR-TKIs
achieved responses of approximately 10% in phase III
clinical trials in patients with previously treated, unse-
lected patients with advanced NSCLC [8,9]. Responses of
EGFR-TKIs were more likely among certain patients:
women, never- or light-smokers, patients with adenocar-
cinoma, and Asians [10-12]. In 2004, somatic mutations
in the kinase domain of EGFR were predominantly
found in these patients and were linked to EGFR-TKI
sensitivity [13-15]. More than 90% of these mutations are
observed in two hotspots: in-frame deletions including
amino acids at codons 747 to 749 in exon 19, and an
amino acid substitution at codon 858 (L858R) in exon 21
[16-18]. These mutations are postulated to mediate
oncogenic effects by altering downstream signaling and
anti-apoptotic mechanisms [13-15]. Prior trials con-
firmed that the response rate to EGFR-TKI in NSCLC
patients with EGFR mutations is approximately 70–
80% [12,19,20], and results of recent phase III trials
showed that the oral EGFR-TKI gefitinib has a superior
progression-free survival (PFS) to standard chemother-
apy as the first-line therapy for NSCLC with mutated
EGFR [21,22].
Mutations are found frequently in individuals of East-
Asian ethnicity (30%), and there are expected clinical
benefits to gefitinib treatment in these patients [23]. Forelderly patients with advanced NSCLC and wild-type
EGFR, single-agent chemotherapy with a third-gener-
ation agent can be considered to be a recommended op-
tion. To maximize the effect of treatment, customized
treatment based on EGFR mutation status would be
mandatory. To evaluate the clinical feasibility and effi-
cacy of such customized therapies, we conducted a pro-
spective clinical trial that included patient assignment
based on EGFR mutation status.Methods
Eligibility
The study was a phase II, open-label, non-randomized,
multicenter study (a phase II study of Iressa versus
Vinorelbine or gemcitAbine in chemo-naïve elderly
patients with advanced Non-small-cell lung cancer
based on epidermal growth factor receptor mutation
status: IVAN Trial; University hospital Medical Informa-
tion Network-clinical trial registration number,
C000000436). Patients enrolled in the present study had
measurable, pathologically confirmed stage IIIB or IV
NSCLC and were aged 70 years or older. Availability of
archived tumor tissue or pleural/pericardial fluid for
evaluation of EGFR mutation status was required for
enrollment. Other eligibility criteria included written
informed consent; no prior chemotherapy; Eastern Co-
operative Oncology Group (ECOG) performance status
(PS) 0 or 1; adequate bone marrow, renal, and hepatic
function; and a life expectancy of at least 3 months. Ex-
clusion criteria included symptomatic brain metastasis,
any evidence of interstitial lung disease on chest com-
puted tomography examination, other co-existing malig-
nancies or malignancies diagnosed within the last
5 years other than carcinoma in situ, history of congest-
ive heart failure, unstable angina pectoris or recent his-
tory (within 6 months) of acute myocardial infarction,
uncontrolled cardiac arrhythmia, severe psychiatric ill-
ness, or concurrent disease or condition that would
have made the patient inappropriate for study partici-
pation. The local ethical committees (the Research Eth-
ics Committee of the Institute of Biomedical Research
and Innovation, the Ethics Committee of Kyoto Univer-
sity Graduate School and Faculty of Medicine, the Clin-
ical Research Approval Committee and the Medical
Ethics Committee of Kurashiki Central Hospital, the
Ethics Committee for Clinical Research of Kobe City
Medical Center General Hospital, the Research Ethics
Committee of Kobe City Medical Center West Hos-
pital, and the institutional review board at the Hyogo
Prefectural Amagasaki Hospital) approved the study,
and written informed consent was obtained from each
patient. The study was conducted in accordance with
the Helsinki declaration.
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In the current open-label study, treatment was assigned
based on EGFR mutation status. First, the EGFR gene
mutational status of a biopsy specimen from each pa-
tient was evaluated. Initially, patients were screened for
EGFR mutations in a commercial central laboratory at
SRL in Tokyo. Both the exon 19 deletion mutation and
the L858R point mutation were screened by direct se-
quencing, as described previously [13]. The T790M mu-
tation, which was reported to be associated with
resistance to EGFR-TKI therapy, was also checked, and
the patient was excluded from the study if this mutation
was detected [24]. From June 1, 2007, outsourcing of
EGFR genetic testing was covered by government insur-
ance in Japan, and the protocol was amended to allow
the outsourcing from each institution to commercial
clinical laboratories, either at Mitsubishi Chemical
Medience in Tokyo (peptide nucleic acid-locked nucleic
acid PCR clamp method) [25] or BML, Inc. in Tokyo
(PCR-invader assay) [26]. During the study period, the
methodology for EGFR mutation detection was substan-
tially improved, and direct sequencing was substituted
with highly-sensitive, advanced-generation detecting
technology available in Japan.
Treatment plan
Patients whose tumor contained an EGFR activating mu-
tation received gefitinib (250 mg per day orally). In the
present study, gefitinib was selected as the EGFR-TKI.
Gefitinib was first approved in Japan for treatment of
patients with advanced NSCLC on July 5th, 2002, and
Japanese oncologists had already acquired considerable
experience with this drug at the beginning of the present
study. Patients with no EGFR activating mutation were
treated with cytotoxic chemotherapy: either vinorelbine
25 mg/m2 on Day 1 and 8 (the recommended dose in
Japan) or gemcitabine 1000 mg/m2 on Day 1 and 8. The
choice of the chemotherapy regimen was at the discre-
tion of the attending physician, and a total of three to
six cycles of treatment were required for either treat-
ment regimen. Treatment was continued until progres-
sion of the disease (PD), development of unacceptable
toxicity, patients’ request, or completion of the treat-
ment. Further therapy after PD was permitted in the
protocol.
Dose modification of gefitinib, vinorelbine, or gemcita-
bine was allowed according to the protocol. The gefitinib
dosing schedule could be modified to every second day
for patients with severe toxicity: pulmonary toxicity (ex-
cept for cough, forced expiratory volume in 1 second,
hiccoughs, interstitial pneumonitis/pulmonary infil-
trates)≥ grade 2, or grade 3/4 diarrhea, mucositis, liver
dysfunction, hematologic toxicity, skin toxicity, or ocular
toxicity. For vinorelbine, a maximum of one dosereduction (25 to 20 mg/m2) was allowed based on the
following criteria: neutropenic fever, ileus ≥ grade 2, non-
hematological toxicity (except for nausea, hyponatremia,
body weight loss, anorexia, and alopecia) ≥ grade 3, grade
4 neutropenia and/or thrombocytopenia. Regarding
gemcitabine, a maximum of one dose reduction (1000 to
800 mg/m2) was allowed based on the following criteria:
neutropenic fever, interstitial pneumonitis or pulmonary
fibrosis≥ grade 1, non-hematological toxicity (except for
nausea, hyponatremia, body weight loss, anorexia, and
alopecia) ≥ grade 3, grade 4 neutropenia and/or
thrombocytopenia.
The primary outcome of the study was the objective
response rate (ORR): partial plus complete response
based on the Response Evaluation Criteria in Solid
Tumors [27]. The present study was designed to detect
a response rate of 65% in the gefitinib group compared
with a minimal, clinically meaningful response rate of
30%. It was estimated before starting the present study
that 20 eligible patients would allow the study to have
80% power to detect this difference, with an alpha level
of 0.05. The drop rate was considered to be 10%, and a
total of 22 patients would need to be enrolled in the
gefitinib group. We estimated that the frequency of
NSCLC with EGFR mutations accounted for 25% of the
total NSCLC population, based on the results of the pre-
protocol survey regarding the number of newly referred
advanced NSCLC patients to two hospitals (Kyoto Uni-
versity Hospital and the Institute of Biomedical Research
and Innovation Hospital; data not shown). To enroll 22
patients in the gefitinib group, 88 patients would need to
be screened, and 66 of the 88 patients were expected to
have tumors with wild-type EGFR. To detect a response
rate of 20% compared with a minimal, clinically mean-
ingful response rate of 5% in the single-agent chemo-
therapy group, 27 patients were required to maintain
more than 80% power to detect this difference, with an
alpha level of 0.05. Sixty-six patients, estimated in the
pre-protocol period, were sufficient. We expected that
patients who had predictive factors for containing an
EGFR mutation (i.e. female, East-Asian origin, adenocar-
cinoma, and no history of smoking) were more likely to
be recruited in our trial. In other words, patients with
wild-type EGFR would be less likely to be enrolled. In
this case, 27 patients were minimally required to detect
the difference in the single-agent chemotherapy group.
The drop rate was considered to be 10%, and a total of
30 patients would need to be enrolled in the single-agent
chemotherapy group.
Planned secondary outcomes included the disease con-
trol rate, 1-year survival rate, overall survival (OS), time
to treatment failure (TTF), and toxicity. Disease control
was defined as the best response out of complete re-
sponse, partial response, or stable disease, which was
Figure 1 Study flow.
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measured from the start date of treatment to the date of
discontinuation of the study treatment, occurrence of
PD, or death by any cause (whichever occurred earlier).
If intolerable toxicity or discontinuation of treatment
secondary to toxicity occurred, the patient was consid-
ered assessable but was classified as a treatment failure.
During treatment, assessments were performed every
6 weeks until disease progression. Events were con-
firmed twice via source-document verification at site vis-
its or delivered radiographic data by members of the
data center and the investigators.
Safety was monitored by clinical AEs, laboratory
(hematology and clinical chemistry) testing, radiographic
information, and collection of vital signs, weight, and
ECOG PS status. AE severity was graded based on the
National Cancer Institute Common Toxicity Criteria
(version 3.0). Interstitial pneumonitis was the most ser-
ious concern related to gefitinib treatment because this
event has been noted in patients taking gefitinib.
OS and TTF were estimated by the Kaplan–Meier
method, and the therapy arms were compared by log-
rank test. Categorical variables were analyzed by Fisher’s
exact test or Χ2 test. Continuous variables were assessed
with unpaired t-tests or the Mann–Whitney U-test. Stat-
istical analyses were performed using JMP version 6
(SAS Institute, Cary, NC, USA) and R software version




Enrollment started in July 2006. From June 2007, the
rate of enrollment slowed, mainly because government
insurance coverage of EGFR genetic analysis had begun
in Japan, and the benefit of enrollment in the present
study was substantially lessened. The last patient was en-
rolled in April 2009. The data cut-off date used for the
present report was February 10, 2011.
Patients
Fifty-seven patients were screened from July 2006 to
April 2009 (Figure 1). Mutational analysis for one pa-
tient was unsuccessful because the amount of the speci-
men was insufficient. During analyses, two patients
suffered serious illnesses not related to their cancer
(acute atherothrombotic ischemic stroke of the right
cerebrum in one patient and congestive heart failure due
to constrictive pericarditis in another patient). These
patients were deemed ineligible. Of the remaining 54
patients, 22 patients (41%) harbored mutations and 32
patients’ tumors were wild type. There was no patient
whose tumor revealed the T790M mutation in exon 20,
and all 54 patients were enrolled in the study. Thedemographic information of the patients is summarized
in Table 1. As expected, some imbalances were observed
between the treatment groups; more never-smokers
(73% vs. 41%) and patients with adenocarcinoma hist-
ology (95% vs. 50%) were in the gefitinib group. These
imbalances seemed to reflect the epidemiologic features
of NSCLC harboring activating EGFR mutations. At the
data cut-off, the median follow up was 15.8 months.Response and survival of the gefitinib group
A summary of the tumor response is shown in Table 2.
The ORR was 45.5% (95% confidence interval [CI],
24.4–67.8%) and disease control rate was 86.4% (95% CI,
65.1–97.1%) for the gefitinib group. Eleven patients had
died among the gefitinib group. The Kaplan–Meier esti-
mate of the median TTF was 9.7 months (Figure 2) and
the median survival time (MST) was 27.9 months (Fig-
ure 3). The 1-year OS rate was 90.0%.Response and survival of the vinorelbine/gemcitabine
group
As shown in Table 2, the ORR was 18.8% (95% CI, 7.2–
36.4%) and the disease control rate was 56.3% (95% CI,
37.7–73.6%) for the vinorelbine (VNR)/gemcitabine
(GEM) group. Twenty-two patients had died among the
VNR/GEM group. The Kaplan–Meier estimate of the
median TTF was 2.9 months (Figure 4) and MST was
14.9 months (Figure 5). The 1-year OS rate was 60.1%.
Table 1 Patient characteristics
All Gefitinib VNR or GEM P
Age (years)
Median (range) 80 (71–89) 81 (71–85) 79 (72–89) 0.11
Male:Female 20:34 5:17 15:17 0.09
ECOG PS
0:1 12:42 8:14 4:28 0.05
Histology
Adeno 37 21 16 < 0.001
Squamous 8 1 7
Other 9 0 9
Smoking history
Never 29 16 13 0.03
Former / current 25 6 19
Mutation type
Exon 19 del 6 6 - -
Exon 21 L858R 14 14 -
Ex19del + L858R 2 2 -
Clinical stage
IIIB 20 9 11 0.78
IV 34 13 21
ECOG PS: Eastern Cooperative Oncology Group Performance Status; GEM:
gemcitabine; VNR: vinorelbine.















Figure 2 Time to treatment failure of the gefitinib group.
1.0
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groups
The baseline characteristics were different between the
gefitinib and VNR/GEM groups because of the non-
randomized nature of the study; however, a statistically
significant difference was found regarding the disease
control rate (86.4% vs. 56.3%; P= 0.035), but not regard-
ing the ORR (45.5% vs. 18.8%; P= 0.067). Concerning
the TTF, a statistically significant difference was
observed between the groups (log-rank test; P= 0.0008;
Figure 6). Additionally, a significantly longer OS was
noted in the gefitinib group compared with the VNR/
GEM group (log-rank test; P= 0.016; Figure 7), although
there was a distinct difference between tumors in eachTable 2 Best response according to RECIST in both
groups
Gefitinib (N= 22) VNR or GEM (N=32)
Complete response 0 0
Partial response 10 (45.5%) 6 (18.8%)
Stable disease 9 (40.9%) 12 (37.5%)
Progressive disease 1 (4.5%) 6 (18.8%)
Not evaluable 2 (9.1%) 8 (25.0%)
GEM: gemcitabine; RECIST: Response Evaluation Criteria in Solid Tumors; VNR:
vinorelbine.group with regard to the EGFR mutation status. For all
patients, the MST was 19.7 months (Figure 8).
Second-line therapy
Of the 22 patients assigned to gefitinib, 14 received
chemotherapy, 5 received radiotherapy, and 8 received
EGFR-TKI (six received erlotinib, two underwent re-
challenge with gefitinib); 2 received no therapy post-
study. Of the 32 patients assigned to single-agent
chemotherapy, 14 received second-line chemotherapy, 8
received radiotherapy, and 15 patients received EGFR-
TKI (nine received erlotinib and six received gefitinib);
five patients received no therapy post-study. No patient
in the single-agent chemotherapy group was in the
protocol-treatment phase.
Toxicity
Toxicity information was available for all 54 treated
patients. Treatment-related AEs were observed in 52 of
the 54 treated patients. No treatment-related deaths
occured in the gefitinib or VNR/GEM groups. AEs oc-
curring in more than 10% of either treatment group are






























Figure 4 Time to treatment failure of the chemotherapy group.
















P=0.0008 by log−rank test
Figure 6 Kaplan–Meier curve of TTF according to the treatment
group.
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frequently occurring grade 3 or worse AE was elevation
of aminotransferase. No interstitial lung disease was
observed. Eleven patients (52%) in the gefitinib group
had at least one drug discontinuation due to AEs; eleva-
tion of aminotransferases in six patients and skin toxicity
in five patients.
As expected, hematologic AEs were common in the
VNR/GEM group (Table 3). Grade 3 or 4 neutropenia,
anemia, and thrombocytopenia occurred in 15 patients
(47%), four patients (13%), and one patient (3%), respect-
ively. Febrile neutropenia was observed in four patients
(13%). The most common grade 3 or 4 non-hematologic
AE in the VNR/GEM group was anorexia followed by fa-
tigue, nausea, and hyponatremia. Dose reduction or
treatment delay was documented in 14 patients (44%)
due to neutropenia or neutropenic fever (eight patients),
fever (three patients), patients’ request (two patients), or
grade 3 constipation (one patient).
Discussion
In the present study, the median TTF and MST of















Figure 5 Overall survival of the chemotherapy group.9.7 months and 27.9 months, respectively, which were
comparable to the results of two recent trials. The North
East Japan 002 Gefitinib Study Group conducted a phase
III trial comparing an EGFR mutation-positive group of
patients receiving gefitinib with carboplatin plus pacli-
taxel [21]. In the planned interim analysis, the PFS was
significantly longer in the gefitinib group and the study
was terminated. The gefitinib group had a significantly
longer PFS compared with the chemotherapy group
(10.8 months vs. 5.4 months, respectively; hazard ratio,
0.30; P <0.001). The MST for the gefitinib group was
30.5 months. Mitsudomi et al., from the West Japan
Thoracic Oncology Group, compared gefitinib with cis-
platin plus docetaxel as the first-line treatment for
advanced NSCLC with EGFR mutations [22]. The gefiti-
nib group had a significantly longer PFS compared with
the cisplatin plus docetaxel group, with a median PFS of
9.2 months vs. 6.3 months, respectively (hazard ratio,
0.489; P <0.0001). These results represent a milestone
















P=0.016 by log−rank test
Figure 7 Kaplan–Meier curve of OS according to the treatment
group.















Figure 8 Kaplan–Meier curve of OS with all trial patients
combined.
Table 3 Adverse events (AEs) occurring in more than 10%
of either treatment group
Gefitinib (N = 22) All Grades CTC Grade 3 or 4
Skin-related AEs 14 (63.6%) 1 (4.5%)
ALT 14 (63.6%) 5 (22.7%)
AST 12 (54.5%) 3 (13.6%)
Anemia 11 (50.0%) 0
Hypoalbminemia 9 (40.9%) 0
Anorexia 6 (27.3%) 0
Fatigue 6 (27.3%) 0
Diarrhea 6 (27.3%) 0
ALP 6 (27.3%) 0
VNR or GEM (N=32) All Grades CTC Grade 3 or 4
Anemia 23 (71.9%) 4 (12.5%)
Leukocytopenia 21 (65.6%) 15 (46.9%)
Neutropenia 20 (62.5%) 15 (46.9%)
Fatigue 18 (56.3%) 2 (6.3%)
Anorexia 12 (37.5%) 3 (9.4%)
Thrombocytopenia 12 (37.5%) 1 (3.1%)
ALT 12 (37.5%) 0
Nausea 11 (34.4%) 2 (6.3%)
Constipation 9 (28.1%) 1 (3.1%)
AST 9 (28.1%) 0
Hyponatremia 5 (15.6%) 2 (6.3%)
Hyperkalemia 5 (15.6%) 0
Hypocalcemia 5 (15.6%) 0
Febrile neutropenia 4 (12.5%) 4 (12.5%)
AE: adverse event; ALT: alanine aminotransferase; ALP: alkaline phosphatase;
AST: aspartate aminotransferase; CTC: common toxicity criteria; GEM:
gemcitabine; VNR: vinorelbine.
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NSCLC patients with EGFR activating mutations in Eur-
ope. Elderly patients have less of a chance of receiving
second-line chemotherapy compared with their younger
counterparts, due to poor organ function and/or comor-
bidities [28], and many elderly patients with relapsed or
refractory NSCLC after first-line chemotherapy are
deemed unfit for second-line chemotherapy [29]. Up-
front administration of the most effective regimen (i.e., a
regimen that is expected to have the longest PFS) is
needed for these patients. The use of first-line gefitinib is
valuable for elderly patients with EGFR mutant NSCLC.
No significant unexpected toxicity was found in the
gefitinib group. Similar to other EGFR-targeted agents,
skin-related AEs were the most common toxicity
observed. No interstitial lung disease was reported. The
Grade 3 to 4 elevation of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) was
observed in 22.7% and 13.6% of patients who received
gefitinib, respectively. This result was comparable to pre-
vious studies conducted in Japan. The most common
toxicity criteria (CTC)-AE grade 3 or 4 toxicity reported
in the gefitinib group of the North East Japan 002 trial
was aminotransferase elevation (26.3%) [21]. In the West
Japan Thoracic Oncology Group 3405 trial, 14 of 87
patients (16.1%) experienced CTC-AE grade 3 or 4 AST
elevation, and grade 3 or 4 ALT elevation was observed
in 24 of 87 patients (27.6%) [22]. This liver enzyme ele-
vation is almost always reversible; however, it may cause
a decrease in dose intensity and may lessen efficacy.
The ORR in the gefitinib group was 45%, which
seemed to be low compared with that reported in the lit-
erature [12,19,20]. One cause may be the high drug-
discontinuation rate due to AEs. In the gefitinib group,
11 patients (50%) had drug discontinuation and dose in-
tensity was lessened, which explains the low ORR in the
gefitinib group. In the present study, all participantswere aged 70 years or older, and the median age of the
enrolled patients was 80 in the entire treatment popula-
tion. Age-related decreases in organ function have the
potential to increase drug-related toxicity in the elderly,
although chronological age itself should not preclude ap-
propriate treatment. Given the favorable TTF and OS in
the gefitinib group, gefitinib was just as effective in the
elderly with mutated EGFR compared with their younger
counterparts. A comprehensive guide on dose adjust-
ments in this population is mandatory, even for this re-
cently developed, molecular-targeted agent.
Monotherapy with vinorelbine, gemcitabine, or doce-
taxel is still reasonable for patients with NSCLC of
unknown EGFR mutation status (i.e., both EGFR
mutation-positive and -negative groups combined). In
the key phase III study ELVIS (the Elderly Lung Cancer
Vinorelbine Italian Study) [30,31], 161 chemotherapy-
naïve patients (≥ 70 years old) were randomized to re-
ceive vinorelbine or best supportive care. The ORR was
20% and 1-year survival rate was 32% for patients
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was recorded compared with the control group. In an-
other key phase III study, the Multicenter Italian Lung
Cancer in the Elderly Study, 700 patients were rando-
mized to receive single-agent chemotherapy with vinorel-
bine or gemcitabine, or combination therapy with
vinorelbine plus gemcitabine [32]. Combination treat-
ment had no advantage regarding ORR, time to progres-
sion (TTP), or survival over single-agent therapy. The
ORR was 18%, 16%, and 21% for vinorelbine, gemcita-
bine, and vinorelbine plus gemcitabine, respectively; the
median TTP was 4.5, 4.3, and 4.8 months and MST was
9.0, 7.0, and 7.5 months, respectively. A phase III trial
(West Japan Thoracic Oncology Group 9904), which
compared docetaxel with vinorelbine for the treatment of
elderly patients with advanced NSCLC, demonstrated a
statistically significant improvement in median PFS
(5.5 months vs. 3.1 months, respectively) and ORR
(22.7% vs. 9.9%, respectively; P= 0.019), but no statistical
difference was found regarding the MST (14.3 months
vs. 9.9 months, respectively; P= 0.138) [29]. Recently, the
IFCT-0501 phase III study demonstrated an improved
OS of a platinum-based combination regimen (carbopla-
tin plus paclitaxel) compared with single-agent chemo-
therapy; however, toxicity was an issue, as 9 of 143 (6.3%)
patients died due to treatment-related AEs [33]. While
the survival benefit with doublet chemotherapy is im-
pressive, accompanying toxicity is a concern with this
regimen.
In our study, single-agent chemotherapy was effective
and feasible for the elderly patients with NSCLC who
were wild type for EGFR. The ORR of 18.8% and MST of
14.9 months observed in the single agent chemotherapy
group were compatible to the results of the previous clin-
ical trials mentioned above. The major AEs were related
to myelosuppression, were clinically manageable, and
included no treatment-related deaths. Given the favor-
able results, we suggest that cytotoxic agent monother-
apy should be considered to be the treatment for elderly
patients with NSCLC who are wild type for EGFR.
At first, we planned a subsequent phase III study to
evaluate the customized treatment based on EGFR mu-
tation status, with patients randomized to either a con-
trol (conventional cytotoxic chemotherapy) arm or
experimental (customized treatment) arm. In June 2007,
however, outsourcing of EGFR genetic testing was fully
covered by the health-insurance system in Japan, and
customized treatment based on EGFR mutation status is
a part of the practice for the treatment of NSCLC.
Advanced-generation analytical methods, including
highly-specific, rapid PCR techniques, allow us to detect
EGFR mutations from fluid specimens, such as malig-
nant effusion or aspiration-needle fluid, with satisfactory
sensitivity and specificity. Most of patients with NSCLChave their tumor analyzed when the pathological diagno-
sis is confirmed, and the results of EGFR mutational
analysis are usually available at the beginning of the
first-line chemotherapy. Results of the present study rep-
resent outcomes of the current standard therapy for eld-
erly patients with NSCLC in Japan, although the number
of enrolled patients was small.
Conclusions
This is the first prospective multi-center study in the
elderly population with advanced NSCLC that included
customized treatment based on EGFR mutation status.
The MST of all participants (both groups combined)
was 19.7 months, which was favorable in elderly patients
(aged 70 years or older) with advanced NSCLC.
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